Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07275315 and PF-07264660 in Moderate-Severe Atopic Dermatitis
NCT05995964Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Aug 2023
- Primary completion
- Nov 2026
- Modality
- Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of tilrekimig, ompekimig in atopic dermatitis (AD), sponsored by Pfizer. Started Aug 2023; status: active, not recruiting.
02
Drugs
tilrekimigompekimig
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05995964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05995964.